newsfilter
← Latest News
GlobeNewswire·

Moleculin Announces Exercise of Warrants for $6.8 Million Gross Proceeds

HOUSTON, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat